Interpretation of the application of TB antigen-based skin tests for the diagnosis of TB infection

doi:10.19982/j.issn.1000-6621.20220247

Abstract

Abstract:

The World Health Organization published a rapid communication “TB antigen-based skin tests for the diagnosis of TB infection” in January 2022. Based on the interpretation and analysis of this rapid communication, and combined the status of latent tuberculosis infection and prevention and control in China, the significance of the application of tuberculosis antigen-based skin tests for the prevention and control of latent tuberculosis infection in China was described, and how to better use tuberculosis antigen-based skin tests were also suggested.

Key words: Mycobacterium tuberculosis, Infection, Diagnosis, differential, Skin tests

CLC Number:

R446
R52

Zhu Limei. Interpretation of the application of TB antigen-based skin tests for the diagnosis of TB infection[J]. Chinese Journal of Antituberculosis, 2022, 44(10): 998-1001. doi: 10.19982/j.issn.1000-6621.20220247

References 6

[1]	World Health Organization. Global tuberculosis report 2021, Geneva: World Health Organization, 2021.
[2]	World Health Organization. Global tuberculosis report 2020, Geneva: World Health Organization, 2020.
[3]	World Health Organization. WHO End TB Strategy. Geneva: World Health Organization, 2015
[4]	高磊, 张慧, 胡茂桂, 等. 基于多中心调查数据和空间统计模型的全国结核分枝杆菌潜伏感染率估算. 中国防痨杂志, 2022, 44(1): 54-59. doi: 10.19982/j.issn.1000-6621.20210661. doi: 10.19982/j.issn.1000-6621.20210661
[5]	Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016, 13(10): e1002152. doi: 10.1371/journal.pmed.1002152. doi: 10.1371/journal.pmed.1002152 URL
[6]	Krutikov M, Faust L, Nikolayevskyy V, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. Lancet Infect Dis, 2022, 22(2): 250-264. doi: 10.1016/S1473-3099(21)00261-9. doi: 10.1016/S1473-3099(21)00261-9 URL

[1]	National Clinical Research Centre for Infectious Disease/The Third People’s Hospital of Shenzhen, Peking University Shenzhen Hospital, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Shenzhen Key Laboratory of Inflammatory and Immune Diseases. Expert consensus on diagnosis and treatment of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 869-879.
[2]	Wang Yuxiang, Chen Qiuqi, Yu Xinxin, Zhan Senlin, Zhang Peize, Deng Guofang. 3HP regimen in the treatment of rheumatic diseases complicated with Mycobacterium tuberculosis latent infection:a prospective study [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 906-910.
[3]	Xie Jingyi, Zou Ruifeng, Chen Yulan, Chen Yong, Liu Dongzhou, Hong Xiaoping. Analysis of clinical features and peripheral lymphocyte subsets of systemic lupus erythematosus patients complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 911-916.
[4]	Cheng Xiao, Chen Zhe, Jiao Xuefeng, Yang Nan, Diao Sha, Ni Xiaofeng, Liu Zheng, He Siyi, Zeng Linan, Wan Chaomin, Kang Deying, Wu Bin, Ying Binwu, Zhang Hui, Zhao Rongsheng, Zhang Lingli. Efficacy and safety of recombinant Mycobacterium tuberculosis fusion proteins (EC) for the diagnosis of Mycobacterium tuberculosis infection: A system review [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 917-926.
[5]	Wu Wenqi, Zhong Jianqiu, He Juan, Deng Guofang, Wang Qingwen. The research progress of the reactivation of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 954-959.
[6]	Chen Qiuqi, Han Tingting, Wang Qingwen, Deng Guofang. Recent advances in treatment of latent tuberculosis infection complicated with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 960-965.
[7]	Cheng Jun, Lu Wei. Interpretation of Guideline on tuberculosis infection prevention and control in primary health care institute [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 762-767.
[8]	Dong Xiaowei, Guo Huixin, Zhang Chenchen, Wang Jiawen, He Junlei, Li Guanhai, Li Jianwei, Wen Wenpei. Application value of two-step detection of Mycobacterium tuberculosis infection screening in schools [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 802-807.
[9]	Zhu Ping, Hao Xiaogang, Wang Wei, Chen Bin. Epidemiological characteristics of inactive pulmonary tuberculosis among the elderly in high-endemic rural areas in Quzhou City, Zhejiang Province [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 815-820.
[10]	Ding Xiurong, Liu Jiachen, Chen Shuhua, Kang Yanfang, Wang Chen, Lou Jinli. Analysis of clinical characteristics of bloodstream infection of mycobacteria in AIDS patients [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 821-826.
[11]	Li Yinhong, Liu Fanglin, Lu Zhenhui, Jiang Xin. Study on the mechanism of Oridonin against pathological damage of tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 849-854.
[12]	XIA Hui, ZHENG Yang, SONG Yuan-yuan. Interpretation of the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex issued by World Health Organization [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 641-645.
[13]	LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653.
[14]	DAI Xiao-wei, WANG Nen-han, CHEN Shuang-shuang, YANG Xin-yu, TIAN Li-li, CHEN Hong, ZHANG Hong-tai, LI Chuan-you. Assessing next-generation sequencing for Mycobacterium tuberculosis diagnosis in clinical sputum samples [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 669-679.
[15]	JIA Hong-yan, DONG Jing, ZHANG Zong-de, PAN Li-ping. Progress and clinical application of immunological detection technology for Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 720-726.